Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Reuters
Reuters
Business

China gives go-ahead for human trials of potential COVID-19 vaccine: state media

FILE PHOTO: People wear face masks outside a shopping mall in Beijing as the country is hit by an outbreak of the novel coronavirus, China, March 11, 2020. REUTERS/Thomas Peter

China has given the go-ahead for researchers to begin human safety tests of an experimental coronavirus vaccine in the race to develop a shot against the COVID-19 epidemic that has killed more than 7,000 people worldwide.

Researchers at China's Academy of Military Medical Sciences, - affiliated to the Chinese People's Liberation Army (PLA) -received approval to launch early-stage clinical trials of the potential vaccine starting this week, the ruling Communist Party's People's Daily reported on Tuesday.

Scientists in the United States said on Monday that clinical trials had begun for a vaccine developed by its National Institute of Allergy and Infectious Diseases and the U.S. biotech firm Moderna.

Details in the Chinese clinical trial registration database show that a "Phase 1" test that will examine whether experimental shot is safe in humans aims to recruit 108 healthy people to take part between March 16 and December 31.

The trial will be conducted by China's Academy of Military Medical Sciences and the Hong Kong-listed biotech firm CanSino Biologics, the database showed.

Experts at the World Health Organization say they do not expect any fully tested and approved vaccine to reach the market until the middle of next year.

(Reporting by Roxanne Liu and Gabriel Crossley; editing by Kate Kelland and John Stonestreet)

Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.